Business Context and Reporting Period
The supplied filing is MultiPlan Corporation’s unaudited Form 10-Q for the quarter and six months ended June 30, 2022, rather than a filing identified as Claritev Corp. MultiPlan provides healthcare data analytics and technology-enabled cost-management, payment-integrity and provider-network services to healthcare payors in the United States. The company reports as a single operating segment.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2022 | Six Months Ended June 30, 2022 |
|---|---|---|
| Revenue | $290.1 million | $588.2 million |
| Operating income | $97.8 million | $214.4 million |
| Operating margin | 33.7% | 36.5% |
| Net income | $13.5 million | $57.5 million |
| Net margin | 4.7% | 9.8% |
| Adjusted EBITDA | $209.6 million | $435.0 million |
| Adjusted EBITDA margin | 72.3% | 73.9% |
| Adjusted EPS | $0.14 | $0.30 |
| Cash flow from operations | Not separately provided | $235.6 million |
Revenue was $290.1 million in the second quarter and $588.2 million year to date. Six-month revenue consisted primarily of Analytics-Based Services of $389.4 million, Network-Based Services of $132.0 million and Payment and Revenue Integrity Services of $66.7 million.
At June 30, 2022, cash and cash equivalents were $354.3 million, restricted cash was $2.8 million, and total current assets were $469.3 million. The company reported $448.2 million of borrowing availability under its revolving credit facility, subject to $1.8 million of outstanding letters of credit.
Long-term debt, net, was $4.88 billion, including the Term Loan B, 5.50% Senior Secured Notes, 5.750% Senior Notes and Senior Convertible PIK Notes. Total debt had an annualized weighted-average cash interest rate of 5.8%. Cash interest paid during the first six months was $139.0 million.
Material Changes Versus the Prior Comparable Period
- Second-quarter revenue increased $13.9 million, or 5.0%, and six-month revenue increased $57.0 million, or 10.7%, versus the corresponding 2021 periods.
- Analytics-Based Services revenue increased 13.2% in the quarter and 18.7% year to date, primarily due to higher medical charges processed and related savings.
- Network-Based Services revenue decreased 12.0% in the quarter and 6.6% year to date, primarily due to client attrition and lower medical charges processed.
- Payment and Revenue Integrity Services revenue was essentially flat in the quarter and increased 8.1% year to date, partly reflecting $5.7 million of revenue from DHP in the year-to-date period.
- Operating income increased 8.9% in the quarter and 24.6% year to date. Net income improved from a $46.9 million loss to $13.5 million of income in the quarter and from a $1.1 million loss to $57.5 million of income year to date.
- Interest expense increased 13.6% in the quarter and 12.9% year to date, reflecting higher LIBOR-based rates and the August 2021 refinancing.
- The change in fair value of private-placement warrants and unvested founder shares shifted from an $81.6 million loss in second-quarter 2021 to a $5.1 million loss in second-quarter 2022. For the six-month periods, the item shifted from a $41.2 million loss to a $7.6 million gain.
- Operating cash flow increased 15.3% to $235.6 million for the first six months, while investing cash outflows declined to $58.1 million from $180.9 million in the prior-year period, which included the $149.7 million DHP acquisition.
Guidance, Outlook, Risks and Unusual Items
The filing does not provide specific quantitative revenue or earnings guidance. Management stated that cash on hand and revolving-credit availability should be sufficient to meet working capital, capital expenditure and other cash requirements for at least the next twelve months, subject to business and market conditions.
COVID-19 continued to reduce revenue because non-COVID medical procedures and services had not returned to pre-pandemic levels. Management indicated that the impact was less severe than in 2020 and 2021, but future effects remain uncertain.
Reported results include substantial amortization of acquired intangible assets, noncash warrant and founder-share fair-value changes, stock-based compensation, integration and transaction-related expenses, and significant interest expense. Adjusted EBITDA and Adjusted EPS are non-GAAP measures and exclude items that may recur or require cash.
Key risks include customer concentration and attrition, pricing pressure, provider-network changes, healthcare regulation, cybersecurity and information-technology disruptions, acquisition integration, inflationary wage pressure, the ability to service substantial debt, and the transition from LIBOR to an alternative reference rate. Three customers accounted for 34%, 19% and 10% of 2021 revenue.
The company reported compliance with its debt covenants at June 30, 2022. The Delaware Stockholder Litigation was dismissed as to the company, although it continues against certain former directors and other defendants; MultiPlan has agreed to indemnify certain defendants. No contingent liability accrual was recorded because a potential loss could not reasonably be estimated.
Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is for MultiPlan Corporation, ticker MPLN, not Claritev Corp.
- Reconcile reported GAAP earnings with Adjusted EBITDA and Adjusted EPS, particularly the effects of amortization, interest expense and warrant fair-value changes.
- Monitor Network-Based Services revenue, customer attrition and the concentration of revenue among major customers.
- Assess the sustainability of operating cash flow relative to approximately $4.9 billion of net debt and rising variable-rate interest costs.
- Review the maturity, conversion terms and potential dilution from the $1.3 billion Senior Convertible PIK Notes convertible at $13.00 per share.
- Evaluate the effect of COVID-19-related healthcare utilization, inflationary wage pressure and LIBOR replacement on future results.
- Verify the status and potential indemnification exposure related to the Delaware Stockholder Litigation and other ordinary-course regulatory or legal matters.